5D-QSAR for spirocyclic sigma1 receptor ligands by Quasar receptor surface modeling.

Based on a contiguous and structurally as well as biologically diverse set of 87 sigma(1) ligands, a 5D-QSAR study was conducted in which a quasi-atomistic receptor surface modeling approach (program package Quasar) was applied. The superposition of the ligands was performed with the tool Pharmacophore Elucidation (MOE-package), which takes all conformations of the ligands into account. This procedure led to four pharmacophoric structural elements with aromatic, hydrophobic, cationic and H-bond acceptor properties. Using the aligned structures a 3D-model of the ligand binding site of the sigma(1) receptor was obtained, whose general features are in good agreement with previous assumptions on the receptor structure, but revealed some novel insights since it represents the receptor surface in more detail. Thus, e.g., our model indicates the presence of an H-bond acceptor moiety in the binding site as counterpart to the ligands' cationic ammonium center, rather than a negatively charged carboxylate group. The presented QSAR model is statistically valid and represents the biological data of all tested compounds, including a test set of 21 ligands not used in the modeling process, with very good to excellent accuracy [q(2) (training set, n=66; leave 1/3 out) = 0.84, p(2) (test set, n=21)=0.64]. Moreover, the binding affinities of 13 further spirocyclic sigma(1) ligands were predicted with reasonable accuracy (mean deviation in pK(i) approximately 0.8). Thus, in addition to novel insights into the requirements for binding of spirocyclic piperidines to the sigma(1) receptor, the presented model can be used successfully in the rational design of new sigma(1) ligands.

[1]  Thierry Langer,et al.  Discovery of high-affinity ligands of σ1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening , 2005 .

[2]  D. Simone,et al.  Enhanced withdrawal responses to heat and mechanical stimuli following intraplantar injection of capsaicin in rats , 1996, PAIN.

[3]  Meyer B. Jackson,et al.  The Sigma Receptor as a Ligand-Regulated Auxiliary Potassium Channel Subunit , 2002, Neuron.

[4]  J. Holenz,et al.  Pharmacological and metabolic characterisation of the potent σ1 receptor ligand 1′‐benzyl‐3‐methoxy‐3H‐spiro[[2]benzofuran‐1,4′‐piperidine] , 2009 .

[5]  V. Ganapathy,et al.  Cloning and Functional Characterization of a σ Receptor from Rat Brain , 1998 .

[6]  P. Casellas,et al.  Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor. , 2001, Biochimica et biophysica acta.

[7]  V. Ganapathy,et al.  Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). , 1996, Biochemical and biophysical research communications.

[8]  Glennon Ra.  Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the "deconstruction-reconstruction-elaboration" approach. , 2005 .

[9]  M. Low,et al.  K+ channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors , 1999, The Journal of physiology.

[10]  B. Wünsch,et al.  Synthesis and structure-affinity relationships of novel spirocyclic sigma receptor ligands with furopyrazole structure. , 2008, Bioorganic & medicinal chemistry.

[11]  H. Glossmann,et al.  The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. , 1997, Trends in pharmacological sciences.

[12]  B. Wünsch,et al.  1,4-Diazepanes derived from (S)-serine--homopiperazines with improved sigma(1) (sigma) receptor affinity and selectivity. , 2009, European journal of medicinal chemistry.

[13]  P. Kadaba,et al.  Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents , 1997 .

[14]  Bernhard Wünsch,et al.  Novel sigma receptor ligands. Part 2. SAR of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] with carbon substituents in position 3. , 2002, Journal of medicinal chemistry.

[15]  G. Skuza.  Potential antidepressant activity of sigma ligands. , 2003, Polish journal of pharmacology.

[16]  A. Vedani,et al.  Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen receptor. , 2005, Journal of medicinal chemistry.

[17]  Max Dobler,et al.  5D-QSAR: the key for simulating induced fit? , 2002, Journal of medicinal chemistry.

[18]  M. Rowley,et al.  Current and novel approaches to the drug treatment of schizophrenia. , 2001, Journal of medicinal chemistry.

[19]  J. Holenz,et al.  Synthesis of sigma receptor ligands with unsymmetrical spiro connection of the piperidine moiety. , 2009, European journal of medicinal chemistry.

[20]  T. Su,et al.  Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity , 2005, Neuroreport.

[21]  P. Acton,et al.  Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. , 2001, Nuclear medicine and biology.

[22]  G. Debonnel,et al.  Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus , 2005, Synapse.

[23]  R. Fröhlich,et al.  Dancing of the second aromatic residue around the 6,8-diazabicyclo[3.2.2]nonane framework: influence on sigma receptor affinity and cytotoxicity. , 2009, Journal of medicinal chemistry.

[24]  G. Gudelsky.  Biphasic effect of sigma receptor ligands on the extracellular concentration of dopamine in the striatum of the rat , 1999, Journal of Neural Transmission.

[25]  E. Kempner,et al.  Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Wünsch,et al.  Novel spiropiperidines as highly potent and subtype selective σ-receptor ligands. Part 1 , 2002 .

[27]  M. Scheunemann,et al.  Synthesis of spirocyclic sigma1 receptor ligands as potential PET radiotracers, structure-affinity relationships and in vitro metabolic stability. , 2009, Bioorganic & medicinal chemistry.

[28]  J. Holenz,et al.  Thiophene bioisosteres of spirocyclic sigma receptor ligands. 1. N-substituted spiro[piperidine-4,4'-thieno[3,2-c]pyrans]. , 2008, Journal of medicinal chemistry.

[29]  E. Aydar,et al.  Sigma Receptors and Cancer , 2004, Cancer Research.

[30]  B. Wünsch,et al.  Synthesis of bridged piperazines with σ receptor affinity , 2007 .

[31]  A. Hajipour,et al.  Characterization of the cocaine binding site on the sigma-1 receptor. , 2007, Biochemistry.

[32]  F. Monnet.  Sigma‐1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance , 2005, Biology of the cell.

[33]  B. Wünsch,et al.  Asymmetric synthesis and σ receptor affinity of enantiomerically pure 1,4-disubstituted tetrahydro-1H-3-benzazepines , 2009 .

[34]  B. Wünsch,et al.  Asymmetric synthesis of enantiomerically pure 2-substituted tetrahydro-3-benzazepines and their affinity to sigma1 receptors. , 2009, The Journal of organic chemistry.

[35]  R. Fröhlich,et al.  Synthesis of Bicyclic σ Receptor Ligands with Cytotoxic Activity , 2007 .

[36]  Peter Zbinden,et al.  Quasi-Atomistic Receptor Surface Models: A Bridge between 3-D QSAR and Receptor Modeling , 1998 .

[37]  W. Bowen.  Sigma receptors: recent advances and new clinical potentials. , 2000, Pharmaceutica acta Helvetiae.

[38]  P. Bednarski,et al.  Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their sigma receptor affinity and cytotoxic activity. , 2009, Bioorganic & medicinal chemistry.

[39]  T. Maurice,et al.  Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  R. Mach,et al.  Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. , 2007, Journal of medicinal chemistry.

[41]  A. Hajipour,et al.  Identification of Regions of the σ-1 Receptor Ligand Binding Site Using a Novel Photoprobe , 2007, Molecular Pharmacology.

[42]  H Briem,et al.  Multiple-conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. , 2000, Journal of medicinal chemistry.